Study of Efficacy and Safety and of AIN457/Secukinumab in Patients With Rotator Cuff Tendinopathy
Status:
Not yet recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the efficacy and safety of AIN457 (secukinumab
s.c.) compared to placebo in adult patients with moderate to severe rotator cuff tendinopathy
and failure to conventional therapy.
- The study duration will be 24 weeks.
- The treatment duration will 12 weeks with 12 weeks follow-up.
- The visit frequency will be weekly until visit 7 and 4-weekly until end of treatment and
4 follow-up visits.